| Patent Number |
Title Of Patent |
Date Issued |
| 6617360 |
Medical treatment |
September 9, 2003 |
| A compound of formula I ##STR1##or a pharmaceutically acceptable salt thereof in which R.sub.1 and R.sub.2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for |
| 6509493 |
Method for producing atropic acid ethyl ester |
January 21, 2003 |
| A process for preparing ethyl atropate by reacting ethyl phenylacetate with paraformaldehyde in the presence of a base is described and entails employing as ethyl phenylacetate a product which contains not more than 0.03% of the corresponding methyl phenylacetate, and carrying out the |
| 6500830 |
Conversion of modification D to modification A of doxazosin mesylate |
December 31, 2002 |
| A process for preparing doxazosin mesylate in modification A which comprises dissolving doxazosin with methanesulfonic acid in methanol or a mixture of an aprotic, polar organic solvent and methanol, removing any turbidity from the resulting solution, and stirring the resulting clear |
| 6458842 |
Liquid pharmaceutical compositions comprising thyroid hormones |
October 1, 2002 |
| There is disclosed a liquid pharmaceutical composition comprising a therapeutic agent which comprises: one or more thyroid hormone or hormones; from about 40% to about 96% ethanol by volume; a pH adjusting agent so that the measured pH of the composition is from about 9 to about 12; |
| 6353002 |
Therapeutic agents |
March 5, 2002 |
| Compounds of formula I ##STR1##and pharmaceutically acceptable salts thereof in which A is methylene or --O--; B is methylene or --O--; G.sub.1 --G.sub.2 --G.sub.3 form a heteroaromatic or heteroaliphatic chain; g is 0, 1 or 2; U is an alkylene chain optionally substituted by one or |
| 6326496 |
Process for preparing an intermediate in the production of paroxetine |
December 4, 2001 |
| A process for the preparation of a compound of formula I ##STR1##in which R.sub.1 represents an amine protecting group wherein a compound of formula II ##STR2##in which R.sub.1 is as defined above is reduced by a metal hydride in the presence of an inorganic salt in the presence of a |
| 6312687 |
Stabilized lactoperoxidase and glucose oxidase concentrate |
November 6, 2001 |
| A stabilized aqueous enzyme concentrate composition which comprises:a) 1000 to 1800 units/ml of lactoperoxidase;b) 1500 to 2750 units/ml of glucose oxidase;c) 10 to 20% w/v of an alkali metal halide salt; andd) a chelating buffering agent present in an amount such that the pH of the composition |
| 6271348 |
Tetracycline-inducible transcriptional inhibitor fusion proteins |
August 7, 2001 |
| Methods of regulating gene expression in subjects using tetracycline-responsive fusion proteins are disclosed. In one embodiment, the method involves introducing into a cell the subject a nucleic acid molecule encoding a fusion protein which inhibits transcription, the fusion protein |
| 6251945 |
Pharmaceutical mixture comprising a combination of a profen and other active compounds |
June 26, 2001 |
| A pharmaceutical mixture comprising a profen and one or more additional active compounds is described which has a total active compound content of over 85% and contains up to 1%, based on the content of the profen, of a nonionic surfactant having an HLB of .gtoreq.9 and a customary d |
| 6239165 |
Liquid pharmaceutical formulation containing zotepine |
May 29, 2001 |
| A liquid pharmaceutical formulation comprising a) 2 to 7% w/v of Zotepine; b) 0.5 to 35% w/v of an organic acid selected from the group consisting of ascorbic acid, citric acid, fumaric acid, glutaric acid, lactic acid, malic acid, sorbic acid and tartaric acid; c) 15 to 60% v/v of ethan |
| 6235281 |
Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level |
May 22, 2001 |
| The invention relates to the use of TNF antagonists for producing drugs for the treatment of disorders characterized by elevated serum levels of interleukin-6. |
| 6225469 |
Process for the preparation of 7-alkoxyalkyl-1,2,4-triazolo[1,5-A] pyrimidine derivatives |
May 1, 2001 |
| An improved process for the preparation of 1,2,4-triazolo[1,5-a]pyrimidine compounds comprising the reaction involving a compound of formula II ##STR1##and a compound of formula III ##STR2##in the presence of an oxidizing agent and a reducing agent, wherein a metal salt is added to f |
| 6218405 |
Heteroarylsulfonamide derivatives and pharmaceutical compositions containing them |
April 17, 2001 |
| Compounds of formula (I) and pharmaceutically acceptable salts thereof in which A is methylene or --O--; B is methylene or --O--; G.sub.1 --G.sub.2 --G.sub.3 form a heteroaromatic or heteroaliphatic chain; g is 0, 1 or 2; U is an alkylene chain optionally substituted by one or more alkyl |
| 6215001 |
Imidazole derivatives as therapeutic agents |
April 10, 2001 |
| Compounds of the formula I ##STR1##and pharmaceutically acceptable salts thereof in which R.sub.1 represents hydrogen, halo, cyano, cyanoalkyl, alkyl, alkoxy, phenoxy, phenyl, alkoxycarbonyl, --NR.sub.13 R.sub.14, --N(R.sub.15)SO.sub.2 R16, halogenated alkoxy, halogenated alkyl, aryl |
| 6201004 |
Dioxino derivatives and their use as therapeutic agents |
March 13, 2001 |
| Compounds of formula I ##STR1##and pharmaceutically acceptable salts thereof in which A is methylene or --O--; B is methylene or --O--; G.sub.1 --G.sub.2 --G.sub.3 form a heteroaromatic or heteroaliphatic chain; g is 0, 1 or 2; U is an alkylene chain optionally substituted by one or |
| 6200791 |
Method of purifying thrombin-like protease enzymes obtained from snake venom |
March 13, 2001 |
| A process for purifying thrombin-like proteases from snake venoms is described, which consists in freeing the proteases from impurities in three chromatographic steps: a) affinity or anion exchange, b) adsorption onto a glass matrix at alkaline pH values, and c) size exclusion gel or |
| 6197780 |
Method for combating obesity |
March 6, 2001 |
| Diseases caused by obesity are treated with endothelin receptor antagonists. Diseases treated include those frequently associated with obesity such as hypertension, type 2 diabetes, hyperlipidemia, chronic kidney failure, arteriosclerosis and gout. |
| 6197349 |
Particles with modified physicochemical properties, their preparation and uses |
March 6, 2001 |
| Particles comprising(a) a supercooled melt of a poorly water-soluble substance and(b) a stabilizing agent,which have a mean particle size of between 30 and 500 nm, and disperse compositions containing them, as administration forms and delivery systems for drugs, vaccines and other biological |
| 6187820 |
Medical treatment to improve lipid levels |
February 13, 2001 |
| A compound of formula I ##STR1##or a pharmaceutically acceptable salt thereof in which R.sub.1 and R.sub.2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for |
| 6187802 |
Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutica |
February 13, 2001 |
| Compounds of Formula I ##STR1##including pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers, in whichAr is phenyl, naphthyl or benzo[b]thiophenyl, each of which may be optionally substituted; R.sub.1 and R.sub. |
| 6174925 |
Use of sibutramine analogues to prevent the development of diabetes |
January 16, 2001 |
| A compound of formula (I) or a pharmaceutically acceptable salt thereof in which R.sub.1 and R.sub.2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for reduc |
| 6162831 |
Medical treatment to lower uric acid levels |
December 19, 2000 |
| A compound of formula I ##STR1## or a pharmaceutically acceptable salt thereof in which R.sub.1 and R.sub.2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is use |
| 6146626 |
Defined enzyme mixtures for obtaining cells and treating wounds |
November 14, 2000 |
| The invention relates to the use of mixtures of defined composition of purified enzymes from Clostridium histolyticum for obtaining, in a reproducible, standardized manner, cells or tissue fragments from human or animal tissues, and to these enzymes and mixtures thereof; in addition it |
| 6133267 |
Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications |
October 17, 2000 |
| A compound of formula I ##STR1## or a pharmaceutically acceptable salt thereof in which R.sub.1 and R.sub.2 are independently H or methyl (for example 1,1-dimethyl-2-(2-morpholinophenyl)guanidine fumarate) is used for inhibiting the formation of advanced glycosylation end-product |
| 6114334 |
Piperazine derivatives as therapeutic agents |
September 5, 2000 |
| Substituted piperazine compounds of formula I ##STR1## in which HET is a substituted pyrazole, imidazole or 1,2,4-triazole have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia |
| 6107310 |
Heteroarylcarboxamide derivatives for treating CNS disorders |
August 22, 2000 |
| Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which A is methylene or --O--; B is methylene or --O--; G.sub.1 --G.sub.2 --G.sub.3 are absent or form a heteroaromatic chain; g is 0,1,2,3 or 4; U is an alkylene chain optionally substituted by one |
| 6069256 |
Process for the preparation of nizatidine |
May 30, 2000 |
| The present invention relates to a novel process for the preparation of nizatidine, N-[2-[[[2-(dimethylamino)methyl-4-thiazolyl]methyl]thio]ethyl]-N'-methyl-2 -nitro-1,1-ethenediamine, and pharmaceutically acceptable salts thereof, comprising reacting a compound of formula II ##ST |
| 6031109 |
Phenoxy-, phenylthio-, benzoyl-alkyleneaminoalkylene-imidazole derivatives as therapeutic agents |
February 29, 2000 |
| Compounds of formula I ##STR1## where R.sub.1 -R.sub.3, L.sub.1, T, L.sub.2 --N--Q--Y and R.sub.6 are as defined in the specification, and pharmaceutically acceptable salts thereof which are antiinflammatory, antiallergic and immunomodulant agents, compositions containing these c |
| 5935973 |
Heterocyclcarboxamide derivatives and their use as therapeutic agents |
August 10, 1999 |
| Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which A is methylene or O; B is methylene or O; g is 0,1,2,3 or 4; R.sub.1 is an optional substituent; U is an alkylene chain optionally substituted by one or more alkyl; Q represents a divalent grou |
| 5917087 |
Process for producing sodium 1-thyroxine comprising the oxidative coupling of a diido-1-tyrosine |
June 29, 1999 |
| Improvements to a six stage process for production of sodium l-thyroxine from l-tyrosine [described in U.S. Pat. No. 2,889,363 and U.S. Pat. No. 2,889,364 (Baxter)] are described, the improvements comprising the oxidative coupling of a diiodo-l-thyrosine to form a biphenyl ether deri |
| 5905079 |
1,2,4-triazolo[4,3-b]pyridazine derivatives and their use |
May 18, 1999 |
| Certain 1,2,4-triazolo(4,3-b)pyridazines of formula ##STR1## including pharmaceutically acceptable salts thereof, wherein R.sub.1 -R.sub.8 are as defined in the disclosure, for the treatment, prophylaxis and/or inhibition of seizures, neurological disorders such as epilepsy and/o |
| 5888981 |
Methods for regulating gene expression |
March 30, 1999 |
| A method for regulating expression of a tet operator-linked gene in a cell of a subject is disclosed. In one embodiment, the method involves introducing into the cell a nucleic acid molecule encoding a tetracycline-controllable transactivator (tTA), the tTA comprising a Tet repressor |
| 5877175 |
Pharmaceutical compositions |
March 2, 1999 |
| Certain 3-(Pyrimidin-4-yl)-1-phenylpyridazin-4(1H)-ones of formula I ##STR1## including pharmaceutically acceptable salts thereof; in which g is 0,1,2,3,4 or 5;R.sub.1 independently represents halo; andR.sub.2 represents H, C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl or optionally substitu |
| 5869492 |
Condensed thiazole derivatives, having 5-HT receptor affinity |
February 9, 1999 |
| Compounds of formula I ##STR1## in which A is S(O).sub.p or O;p is 0, 1 or 2;g is 0, 1, 2, 3, or 4;n is 2 or 3; andR.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are optional substituents have utility in the treatment of central nervous system disorders, for example depression, anxie |
| 5854257 |
Naphthyridinone derivatives |
December 29, 1998 |
| Compounds of formula I ##STR1## including pharmaceutically acceptable salts thereof in which R.sub.1 represents a phenyl C.sub.1-6 alkyl group (in which the phenyl ring is optionally substituted by one or more of the following: halo, a C.sub.1-4 alkyl group, a C.sub.1-4 alkoxy gr |
| 5847216 |
Preparation of selegiline |
December 8, 1998 |
| A process for preparing selegiline hydrochloride by reaction of R-(-)-N,.alpha.-dimethylphenylethylamine with 3-bromo-1-propyne is described, which consists in reacting the substances in a molar ratio of approximately 2:1 at 30.degree.-50.degree. C. in a solvent mixture of an aromati |
| 5807868 |
Isoquinoline derivatives as therapeutic agents |
September 15, 1998 |
| Tetrahydroisoquinoline compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof, in which: R.sub.1 represents one or more substituents selected from H, halo, hydroxy, alkyl (optionally substituted by hydroxy), alkoxy, alkylthio, alkylsulphinyl, alkyl-sulphony |
| 5807542 |
Chemical compositions for inhibiting nitrosation reaction in toiletries and cosmetics |
September 15, 1998 |
| Iminium ion scavengers are used in the invention to inhibit formation of N-nitrosamines, especially in cosmetics and pharmaceuticals formulations. The iminium ion scavengers may be used in combination with nitrite ion scavengers such as ascorbate. |
| 5804586 |
Therapeutic agents |
September 8, 1998 |
| Tetrahydroisoquinoline compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof, in which: R.sub.1 represents one or more substituents selected from H, halo, hydroxy, alkyl (optionally substituted by hydroxy), alkoxy, alkylthio, alkylsulphinyl, alkyl-sulphony |
| 5780642 |
Imidazole derivatives as therapeutic agents |
July 14, 1998 |
| Compounds of the formula I ##STR1## and pharmaceutically acceptable salts thereof in which R.sub.1 represents hydrogen, halo, cyano, cyanoalkyl, alkyl, alkoxy, phenoxy, phenyl, alkoxycarbonyl, --NR.sub.13 R.sub.14, --N(R.sub.15)SO.sub.2 R16, halogenated alkoxy, halogenated alkyl, |
| 5780482 |
Condensed 4-aminopyridines with antirheumatic activity |
July 14, 1998 |
| Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which one of A or B represents N and the other represents N or C--R.sub.3 ; R.sub.1 represents hydrogen, halo, alkyl, hydroxy, carboxyalkenyl, alkoxycarbonylalkenyl, hydroxyalkyl, carboxyalkyl, alkox |
| 5760035 |
Therapeutic agents |
June 2, 1998 |
| Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which R.sub.1, R.sub.2 and R.sub.3 independently represent hydrogen, hydroxy, halo, alkyl or alkoxy;ALK.sup.1 represents a C.sub.2-6 alkylene chain optionally substituted by one or more C.sub.1-2 alk |
| 5753665 |
Therapeutic agents |
May 19, 1998 |
| Compounds of formula (I) which includes pharmaceutically acceptable salts thereof and stereoisomers thereof: ##STR1## wherein: R.sub.1 represents H or one of the following groups (optionally substituted with one or more of halo, cyano, hydroxy or amino): C.sub.1-6 alkyl, C.sub.1- |
| 5753254 |
Therapeutic agents containing thyroid hormones |
May 19, 1998 |
| There is disclosed a solid fast dispersing dosage form of a pharmaceutical composition suitable for oral administration comprising: a therapeutic agent which comprises one or more compound thyroid hormone or hormones; from about 80% to about 99.9% of disintegrating agent by mass; from ab |
| 5736568 |
2-(aminoalkoxy) phenylalkylamines with antiinflammatory activity |
April 7, 1998 |
| Compounds of the formula I ##STR1## including pharmaceutically acceptable salts thereof are disclosed in which R.sub.1, R.sub.2, R.sub.3, and R.sub.4 independently represent hydrogen, hydroxy, halo, halogenated alkyl, halogenated alkoxy, alkyl, alkoxy, cyano, a carbamoyl group, c |
| 5720973 |
Preparation of colloidal aqueous solutions of active substances of low solubility and a lipid th |
February 24, 1998 |
| A process for producing solutions of active substances of low solubility, which comprises (1) dissolving the active substance with a phospholipid and a water-soluble lipid in an organic solvent, (2) evaporating the resulting solution to dryness, (3) taking up the residue in a strongly |
| 5712286 |
Naphthyridine derivatives |
January 27, 1998 |
| Compounds of formula (I) including pharmaceutically acceptable salts thereof in which R.sub.1 represents a C.sub.1-6 alkyl group; R.sub.2 represents a group of the formula COOR.sub.4 in which R.sub.4 represents a C.sub.1-5 alkyl group; and R.sub.3 represents a group of formula COOR.s |
| 5703089 |
Dihydrodibenzisoquinolinediones |
December 30, 1997 |
| Novel bis-1,2-dihydro-3H-dibenzisoquinoline-1,3-diones and their salts, processes for their preparation, pharmaceutical compositions containing them and methods of using them to treat malignancies, mainly human solid tumor carcinomas. |
| 5681588 |
Delayed release microtablet of .beta.-phenylpropiophenone derivatives |
October 28, 1997 |
| A cylindrical delayed release tablet with a convex or flat upper side and lower side is provided, along with a method for its production and a gelatin capsule containing 3-200 tablets of the same having identical or different release rates, wherein the tablet if made of .beta.-phenyl |
| 5654168 |
Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units |
August 5, 1997 |
| Nucleic acid molecules and proteins useful for regulating the expression of genes in eukaryotic cells and organisms in an inducible manner are disclosed. In the regulatory system of the invention, transcription of a tet operator-linked nucleotide sequence is stimulated by a transcription |
